Application of aminobenzoic acid compound in preparation of medicine for treating Parkinson's disease and complications of Parkinson's disease

Regulating the intestinal flora of Parkinson's patients through aminobenzoic acid compounds, solving the problem of ineffectiveness of existing drugs on intestinal flora and metabolic disorders, significantly improving the symptoms of constipation and metabolic disorders, and using phosphatidylethanolamine Further improve intestinal health and alleviate the disease progression.

CN118903089APending Publication Date: 2024-11-08ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410495272.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing drugs are not effective in the symptoms of intestinal flora and metabolic disorders in patients with Parkinson's disease, and the treatment of motor symptoms has failed to improve the intestinal flora and metabolic disorders in the peripheral colon.

Method used

Aminobenzoic acid compounds are used to prevent and treat intestinal flora and metabolic disorders caused by Parkinson's disease, improve intestinal flora homeostasis by regulating the amount of Dubosiella and Lactococcus in the intestinal tract, and use phosphatidylethanolamine to prevent and Treat intestinal microbial disorders.

Benefits of technology

Significantly improve the intestinal microbiota and metabolic disorders in patients with Parkinson's disease, reduce constipation symptoms, and reduce disease progression through intervention in the early stages, and improve patients' quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903089A_ABST
    Figure CN118903089A_ABST
Patent Text Reader

Abstract

The invention discloses application of an aminobenzoic acid compound in preparation of a medicine for treating Parkinson's disease and complications thereof. In the application, the application of the aminobenzoic acid compound in improving dyskinesia and non-dyskinesia of patients with Parkinson's disease is provided. It is found for the first time that the aminobenzoic acid compound can significantly improve intestinal flora disorder and metabolic disorder concurrent by patients with the Parkinson's disease, is beneficial to maintaining the homeostasis of the peripheral intestinal flora of the patients with the Parkinson's disease, and improves the severe constipation condition of the patients; it is clear that the aminobenzoic acid compound can relieve the disease progress of the Parkinson's disease by intervening in the early stage of the Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to biomedicine, and in particular to use of aminobenzoic acid compounds in preparing medicines for treating Parkinson's disease and its complications. Background Art

[0002] Parkinson's disease (PD) is the second most common neurodegenerative disease in clinical practice. The typical brain pathological characteristics of PD are the death of dopamine (DA) neurons (type A9) in the substantia nigra pars compacta (SNc) of the midbrain and the deposition of Lewy bodies formed by the incorrect tangles of α-synuclein (α-Syn), which accelerate the death of DA neurons, resulting in a decrease in the DA content in the striatum, causing clinical symptoms with movement disorders such as resting tremor, muscle rigidity, bradykinesia, and abnormal posture and gait as the main manifestations, which seriously affect the quality of life of PD patients. In addition, studies have found that the vast majority of PD patients have suffered from gastrointestinal diseases before diagnosis. PD patients often experience gastrointestinal symptoms such as abdominal distension and constipation, which even appear 12 to 18 years earlier than motor symptoms. A large number of PD patients also suffer from gastrointestinal dysfunction, including peripheral colon intestinal flora disorders and metabolic disorders, and the incidence of constipation in PD patients is also significantly higher than that in healthy people. Ordinary drugs for treating intestinal flora disorders or metabolic disorders are usually ineffective for the gastrointestinal functional symptoms exhibited by PD patients. This may be due to the fact that the mechanism of intestinal flora disorders and metabolic disorders in PD patients is different from that of ordinary gastrointestinal dysfunction patients. In the prior art, drugs for the treatment of PD, such as levodopa, carbidopa, selegiline, trihexyphenidyl and benztropine, are mostly developed for motor symptoms. In actual applications, they have almost no improvement effect on the peripheral colon intestinal flora disorders and metabolic disorder symptoms exhibited by PD patients. Therefore, this field urgently needs to develop targeted drugs for improving intestinal flora disorders and metabolic disorders in PD patients to alleviate the suffering of patients. Summary of the invention

[0003] The object of the present invention is to provide a use of aminobenzoic acid compounds.

[0004] Another object of the present invention is to provide a method for treating intestinal flora disorder and / or metabolic disorder caused by Parkinson's disease.

[0005] Another object of the present invention is to provide a use of phosphatidylethanolamine or its promoter.

[0006] In order to solve the above technical problems, the first aspect of the present invention provides a use of an aminobenzoic acid compound for:

[0007] (i) prevention and / or treatment of Parkinson's disease and its complications; and

[0008] (ii) preparing a medicament for preventing and / or treating Parkinson's disease or its complications;

[0009] Among them, the structure of aminobenzoic acid compounds is as follows:

[0010]

[0011] In some preferred embodiments, the complication of Parkinson's disease is non-motor dysfunction caused by Parkinson's disease.

[0012] In some preferred embodiments, the non-motor dysfunction caused by Parkinson's disease includes constipation, intestinal flora disorder and / or metabolic disorder.

[0013] In some preferred embodiments, the complication of Parkinson's disease is a metabolic disorder caused by Parkinson's disease.

[0014] In some preferred embodiments, the complication of Parkinson's disease is intestinal flora disorder caused by Parkinson's disease.

[0015] In some preferred embodiments, aminobenzoic acid compounds are used for:

[0016] (i) Preventing and / or treating intestinal flora disturbance caused by Parkinson's disease;

[0017] (ii) prevention and / or treatment of metabolic disorders caused by Parkinson's disease;

[0018] (iii) preparing a drug for preventing and / or treating Parkinson's disease-induced intestinal flora disturbance; and

[0019] (iv) preparing a medicament for preventing and / or treating metabolic disorders caused by Parkinson's disease.

[0020] In some preferred embodiments, the intestinal flora disorder caused by Parkinson's disease is peripheral colon intestinal flora disorder caused by Parkinson's disease.

[0021] In some preferred embodiments, the intestinal flora is an OS-tolerant intestinal flora.

[0022] In some preferred embodiments, the intestinal flora includes Dubosiella, Faecalibaculum, Coriobacteriaceae-UCG-002, Candidatus-Saccharimon, Lactococcus, norank-f-Ruminococcaceae, Lachnospiraceae-NK4A136-group and / or Bacillus.

[0023] In some preferred embodiments, the aminobenzoic acid compound is used to increase the amount of Dubosiella in the intestine of Parkinson's disease patients, or to inhibit the reduction of Dubosiella in the intestine of Parkinson's disease patients.

[0024] In some preferred embodiments, the aminobenzoic acid compound regulates the intestinal flora disorder of Parkinson's disease patients by increasing the amount of Dubosiella in the intestine of Parkinson's disease patients or reducing the amount of Dubosiella in the intestine of Parkinson's disease patients.

[0025] In some preferred embodiments, the aminobenzoic acid compound is used to reduce the amount of Lactococcus in the intestine of Parkinson's disease patients, or inhibit the increase of Lactococcus in the intestine of Parkinson's disease patients.

[0026] In some preferred embodiments, the aminobenzoic acid compound regulates the intestinal flora disorder of Parkinson's disease patients by reducing the amount of Lactococcus in the intestine of Parkinson's disease patients or increasing the amount of Lactococcus in the intestine of Parkinson's disease patients.

[0027] In some preferred embodiments, the metabolic disorder caused by Parkinson's disease includes: sugar metabolism disorder caused by Parkinson's disease, fat metabolism disorder caused by Parkinson's disease and / or neurotransmitter (preferably, the neurotransmitter includes L-Glutamate and / or L-Glutamic acid) metabolism disorder caused by Parkinson's disease.

[0028] In some preferred embodiments, the fat metabolism disorder caused by Parkinson's disease includes glycerophosphate (preferably phosphatidylethanolamine) metabolism disorder caused by Parkinson's disease.

[0029] The second aspect of the present invention provides a method for preventing and / or treating Parkinson's disease and its complications, comprising the steps of:

[0030] A therapeutically effective amount of an aminobenzoic acid compound is administered to the subject.

[0031] The third aspect of the present invention provides a method for preventing and / or treating intestinal flora disorder caused by Parkinson's disease, comprising the steps of:

[0032] A therapeutically effective amount of an aminobenzoic acid compound is administered to the subject.

[0033] In some preferred embodiments, the intestinal flora includes Dubosiella and / or Lactococcus.

[0034] A fourth aspect of the present invention provides a method for preventing and / or treating metabolic disorders caused by Parkinson's disease, comprising the steps of:

[0035] A therapeutically effective amount of an aminobenzoic acid compound is administered to the subject.

[0036] In some preferred embodiments, the metabolic disorder is a glycerophosphate (preferably phosphatidylethanolamine) metabolic disorder and / or a neurotransmitter (preferably, the neurotransmitter includes L-Glutamate and / or L-Glutamic acid) metabolic disorder.

[0037] A fifth aspect of the present invention provides the use of phosphatidylethanolamine for:

[0038] (i) Preventing and / or treating intestinal flora disturbance caused by Parkinson's disease;

[0039] (ii) preparing a drug for preventing and / or treating intestinal flora disturbance caused by Parkinson's disease.

[0040] Compared with the prior art, the present invention has at least the following advantages:

[0041] (1) The present invention provides the use of aminobenzoic acid compounds in improving motor dysfunction and non-motor dysfunction in patients with Parkinson's disease. The present invention first discovered that aminobenzoic acid compounds can significantly improve intestinal flora disorders and metabolic disorders concurrent with Parkinson's disease patients, help maintain the homeostasis of peripheral intestinal flora in patients with Parkinson's disease, and improve patients' severe constipation;

[0042] (2) The present invention clarifies that aminobenzoic acid compounds can alleviate the disease progression of Parkinson's disease by intervening in the early stages of Parkinson's disease.

[0043] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] One or more embodiments are exemplarily described by the pictures in the corresponding drawings, and these exemplary descriptions do not constitute limitations on the embodiments.

[0045] Figure 1A This is a schematic diagram of the time flow of PD mouse modeling and behavioral testing according to an embodiment of the present invention;

[0046] Figure 1B is a statistical graph of the body weight of each group of mice at the ninth month according to an embodiment of the present invention;

[0047] Figure 1C It is a statistical diagram of the results of the rotarod test of each group of mice according to the embodiment of the present invention (WT-vehicle: n=19, WT-PFF: n=6, WT-PFF-aminobenzoic acid compound: n=7);

[0048] Figure 1D It is a statistical diagram of the results of the pole climbing experiment of each group according to the embodiment of the present invention. (a) Head turning time (b) Total time (WT-vehicle: n=19, WT-PFF: n=6, WT-PFF-aminobenzoic acid compound: n=7);

[0049] Figure 1E It is a statistical diagram of the experimental results of muscle strength test of each group according to the embodiment of the present invention (WT-vehicle: n=19, WT-PFF: n=6, WT-PFF-aminobenzoic acid compound: n=7);

[0050] Figure 1F It is a statistical diagram of the results of the Y-maze experiment of each group according to the embodiment of the present invention, evaluating the effect of aminobenzoic acid compounds on the short-term or working memory of mice (WT-vehicle: n=17, WT-PFF: n=6, WT-PFF-aminobenzoic acid compounds: n=7);

[0051] Figure 2A is the TH of SNc brain region of each group of mice in the embodiment of the present invention + Representative immunofluorescence images of neurons, Scale bar, 200 μm;

[0052] Figure 2B is the TH in each group of SNc according to the embodiment of the present invention. + Unbiased stereological counting data of neurons (WT-vehicle: n = 6, WT-PFF: n = 5, WT-PFF-aminobenzoic acid compounds: n = 4);

[0053] Figure 2C According to the present invention, the striatum IBA of each group of mice + Representative immunofluorescence images of microglia, Scale bar, 50 μm;

[0054] Figure 2D It is a statistical diagram of the number of microglia per unit area of ​​the striatum in each group according to the embodiment of the present invention (WT-vehicle: n=6, WT-PFF: n=5, WT-PFF-aminobenzoic acid compound: n=4);

[0055] Figure 2EIt is a statistical diagram of the number of astrocytes per unit area of ​​the striatum in each group according to the embodiment of the present invention (WT-vehicle: n=6, WT-PFF: n=4, WT-PFF-aminobenzoic acid compound: n=4);

[0056] Figure 2F The relative content of neurotransmitters detected by striatal HPLC-MS according to the embodiment of the present invention is statistically shown as (a) Epinephine, (b) Noradrenaline, (c) DA, (d) HVA (n = 3-4 for the WT-vehicle, n = 4 for the WT-PFF, n = 4 for the WT-aminobenzoic acid compounds). The above data are expressed as Mean ± SEM. Analysis method: One-way ANOVA with multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant;

[0057] Figure 3A The immunofluorescence images in the examples of the present invention show the deposition of pSer129-α-Syn in SNc DA neurons of mice in each group. Scale bar, 100 μm. ;

[0058] Figure 3B It is a statistical heat map of the fluorescence expression of pSer129-α-Syn in a whole brain slice divided into nine regions from Bregma 1.78 to -3.52 mm according to the coordinates of the mouse brain stereotaxic atlas in an embodiment of the present invention;

[0059] Figure 3C Schematic diagram of immunofluorescence staining of pSer129-α-Syn in the Primary motorcortex, Cortex, Striatum, Hippocampal CA1, and Hippocampal dentategyrus of mice injected with PFFs 270 days after injection according to an embodiment of the present invention. Scale bar, 200 μm;

[0060] Figure 4A This is a flow chart of stool test detection according to an embodiment of the present invention. ;

[0061] Figure 4BThis is a statistical result diagram of the stool test in the third month according to the embodiment of the present invention, (a) total weight of stool; (b) water content of stool (WT-vehicle: n=19, WT-PFF: n=18, TRPM2-KO-vehilce: n=14, TRPM2-KO-PFF: n=11);

[0062] Figure 4C 1 is a statistical graph of the feces test results in the sixth month according to an embodiment of the present invention, (a) total weight of feces; (b) water content of feces (WT-vehicle: n=19, WT-PFF: n=18, TRPM2-KO-vehilce: n=14, TRPM2-KO-PFF: n=11);

[0063] Figure 4D This is a statistical graph of the fecal test results for the ninth month according to the embodiment of the present invention. (a) TRPM2-KO intervention group (b) aminobenzoic acid compound intervention group (WT-vehicle: n=6, WT-PFF: n=6, TRPM2-KO-vehilce: n=6, TRPM2-KO-PFF: n=6, WT-PFF-aminobenzoic acid compound: n=6);

[0064] Figure 4E is a schematic diagram of 16S rRNA gene sequencing of a stool sample according to an embodiment of the present invention;

[0065] Figure 4F This is an alpha diversity analysis of community richness according to an embodiment of the present invention: aminobenzoic acid compound intervention group, (a) one-way ANOVA of sobs index; (b) one-way ANOVA of ACE index; (c) one-way ANOVA of chao index. (WT-vehicle: n=6, WT-PFF: n=6, WT-PFF-aminobenzoic acid compound: n=6, TRPM2-KO-vehilce: n=6, TRPM2-KO-PFF: n=6). The above data are expressed as Mean±SEM. Analysis method: One-way ANOVA with multiple comparison test. *P<0.05, **P<0.01, ***P<0.001, ns: not significant;

[0066] Figure 4GThis is an alpha diversity analysis of community richness according to an embodiment of the present invention: TRPM2-KO intervention group, (a) one-way ANOVA of sobs index; (b) one-way ANOVA of ACE index; (c) one-way ANOVA of chao index. (WT-vehicle: n=6, WT-PFF: n=6, WT-PFF-aminobenzoic acid compounds: n=6, TRPM2-KO-vehilce: n=6, TRPM2-KO-PFF: n=6). The above data are expressed as Mean±SEM. Analysis method: One-way ANOVA with multiple comparison test. *P<0.05, **P<0.01, ***P<0.001, ns: not significant;

[0067] Figure 5A The Rank-Abundance curves in the present invention are used to analyze the microbial diversity at the ASV level. Aminobenzoic acid compound intervention group;

[0068] Figure 5B The microbial diversity at the ASV level was analyzed using the Rank-Abundance curve in the embodiment of the present invention. TRPM2 intervention group;

[0069] Figure 5C It is Pan analysis used in the embodiments of the present invention to describe the changes in total species with increasing sample size, that is, the changes in total species richness at the ASV level, aminobenzoic acid compound intervention group;

[0070] Figure 5D According to the embodiment of the present invention, Pan analysis is used to describe the changes in total species with the increase in sample size, that is, the changes in total species richness at the ASV level. TRPM2 intervention group;

[0071] Figure 5E It is the Core species analysis used to describe the changes in the core species volume of the ASV level with the increase of the sample size according to the embodiment of the present invention, the aminobenzoic acid compound intervention group;

[0072] Fig. 5F It is the Core species analysis used to describe the changes in the volume of core species at the ASV level with the increase in sample size according to the embodiment of the present invention, TRPM2 intervention group;

[0073] Fig. 6A is a hierarchical clustering tree of each genus level of the intervention of aminobenzoic acid compounds according to the embodiments of the present invention;

[0074] Figure 6B It is the main related typing analysis of each group genus level of aminobenzoic acid compound intervention according to the embodiment of the present invention;

[0075] Figure 6C Schematic diagram of non-metric multidimensional scaling (NMDS) at Genus (a) and ASV (b) levels according to an embodiment of the present invention;

[0076] Fig.6D is a statistical diagram of the relative abundance of Dubosiella and Coriobacteriaceae UCG 002 in each group intervened by aminobenzoic acid compounds according to the examples of the present invention;

[0077] Fig. 7A is a hierarchical clustering tree of each genus level of TRPM2 intervention according to an embodiment of the present invention;

[0078] Figure 7B It is the main correlation typing analysis of each group genus level of TRPM2 intervention according to the embodiment of the present invention;

[0079] Figure 7C Schematic diagram of non-metric multidimensional scaling (NMDS) on Genus (a) and ASV (b) according to an embodiment of the present invention;

[0080] Fig.7D It is a statistical diagram of the relative abundance of Dubosiella and Coriobacteriaceae UCG 002 in each group of TRPM2 intervention according to an embodiment of the present invention;

[0081] Fig. 8A According to the BugBase phenotype prediction in the embodiments of the present invention, aminobenzoic acid compounds and TRPM2-KO can effectively regulate the intestinal flora associated with OS tolerance;

[0082] Figure 8B is the composition of intestinal flora related to OS tolerance at the genus level according to the embodiments of the present invention;

[0083] Figure 8C is a heat map of the analysis of enzyme changes among groups during community phylogeny using the PICRUSt2 method according to an embodiment of the present invention;

[0084] Fig. 9 According to an embodiment of the present invention, the PICRUSt2 method is used to perform functional prediction analysis, obtain functional changes corresponding to KEGG pathways 1-3 (ab), and display them in the form of a heat map;

[0085] Fig. 10A1 is a schematic diagram of quality control of positive ion expression data preprocessing according to an embodiment of the present invention (the solid line is the data before preprocessing, and the dotted line is the data after preprocessing. The overall data is qualified);

[0086] Fig. 10B 1 is a schematic diagram of quality control of negative ion expression data preprocessing according to an embodiment of the present invention (the solid line is the data before preprocessing, and the dotted line is the data after preprocessing. The overall data is qualified);

[0087] Fig. 10C is the principal component analysis (PCA) of the positive ions (a) and negative ions (b) of the aminobenzoic acid compound intervention group according to the embodiment of the present invention;

[0088] Fig. 10D is the partial least squares discriminant analysis (PLS-DA) of the positive ions (a) and negative ions (b) of the aminobenzoic acid compound intervention group according to the embodiment of the present invention;

[0089] Fig.10E is the principal component analysis (PCA) of positive ions (a) and negative ions (b) in the TRPM2 intervention group according to the embodiment of the present invention;

[0090] Fig.10F is the partial least squares discriminant analysis (PLS-DA) of the positive ions (a) and negative ions (b) of the TRPM2 intervention group according to the embodiment of the present invention;

[0091] Figure 10G is a Venn diagram of each group of metabolites according to an embodiment of the present invention;

[0092] Fig. 10H It is the KEGG compound classification of metabolites according to the embodiments of the present invention;

[0093] Fig.11 This is a heat map of neurotransmitters in the aminobenzoic acid compound intervention group according to an embodiment of the present invention;

[0094] Fig.12 The cluster heat map and VIP bar graph of the aminobenzoic acid compound group according to the embodiment of the present invention are used to show the changes in neurotransmitters between WT-Vehicle and WT-PFF (a), and between WT-PFF and WT-PFF-aminobenzoic acid compound (b). DETAILED DESCRIPTION

[0095] The present invention aims to solve the problem that existing drugs for treating gastrointestinal dysfunction or PD are ineffective for peripheral colon intestinal flora disorder, metabolic disorder and severe constipation in PD patients, and develops a new use of aminobenzoic acid compounds, that is, the symptoms of peripheral colon intestinal flora disorder and metabolic disorder in PD patients are significantly improved. In addition, based on the brain-gut axis theory, the present invention clarifies that aminobenzoic acid compounds / phosphatidylethanolamine and its promoters / Dubosiella / Lactococcus can be used to intervene in the early stage of PD and alleviate the disease progression of PD.

[0096] Uses of aminobenzoic acid compounds

[0097] The present invention relates to a new use of aminobenzoic acid compounds for: (i) preventing and / or treating Parkinson's disease and its complications; and (ii) preparing drugs for preventing and / or treating Parkinson's disease or its complications.

[0098]

[0099] As used in the present invention, the terms "Parkinson's disease" and "PD (Parkinson disease)" are used interchangeably. It is a common neurodegenerative disease in middle-aged and elderly people. Clinically, it is characterized by resting tremor, bradykinesia, muscle rigidity and postural balance disorders. The term "complications of Parkinson's disease" refers to various symptoms caused during the progression of Parkinson's disease, including psychological disorders, digestive system disorders, limb spasms, limb deformities, sleep disorders, constipation, various organ infections such as the respiratory tract / urinary system / lungs, constipation, etc. In a preferred embodiment of the present invention, "complications of Parkinson's disease" are non-motor dysfunction caused by Parkinson's disease; more preferably, constipation, intestinal flora disorders and / or metabolic disorders.

[0100] As used in the present invention, the term "intestinal flora disorder" refers to an imbalance state caused by changes in the composition of intestinal flora, changes in bacterial activity or changes in flora distribution, which is often manifested as diarrhea, abdominal pain, abdominal distension, etc. In an embodiment of the present invention, "intestinal flora disorder" refers to an imbalance in intestinal flora caused by Parkinson's disease, including obvious deviations from normal levels of flora species, quantity, distribution, etc. In a preferred embodiment of the present invention, "intestinal flora disorder" refers to deviations from normal levels of Dubosiella, Faecalibaculum, Coriobacteriaceae-UCG-002, Candidatus-Saccharimon, Lactococcus, norank-f-Ruminococcaceae, Lachnospiraceae-NK4A136-group and / or Bacillus.

[0101] In a preferred embodiment of the present invention, aminobenzoic acid compounds can be used to increase the amount of Dubosiella in the intestines of Parkinson's patients, or to inhibit the reduction of Dubosiella in the intestines of Parkinson's patients; or to reduce the amount of Lactococcus in the intestines of Parkinson's patients, or to inhibit the increase of Lactococcus in the intestines of Parkinson's patients. In a preferred embodiment of the present invention, aminobenzoic acid compounds regulate the intestinal flora disorder of Parkinson's patients by increasing the amount of Dubosiella in the intestines of Parkinson's patients. In a preferred embodiment of the present invention, aminobenzoic acid compounds regulate the intestinal flora disorder of Parkinson's patients by reducing the amount of Dubosiella in the intestines of Parkinson's patients. In a preferred embodiment of the present invention, aminobenzoic acid compounds regulate the intestinal flora disorder of Parkinson's patients by reducing the amount of Lactococcus in the intestines of Parkinson's patients. In a preferred embodiment of the present invention, aminobenzoic acid compounds regulate the intestinal flora disorder of Parkinson's patients by increasing the amount of Lactococcus in the intestines of Parkinson's patients.

[0102] As used in the present invention, the term "metabolic disorder" refers to the phenomenon of metabolic dysfunction in the body. Common ones include glucose metabolism disorder, biosynthesis or conversion dysfunction, etc. In a preferred embodiment of the present invention, "metabolic disorder" refers to a series of metabolic disorders caused by Parkinson's disease, such as glucose metabolism disorder caused by Parkinson's disease, fat metabolism disorder caused by Parkinson's disease and / or neurotransmitter metabolism disorder caused by Parkinson's disease.

[0103] In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to regulate the metabolic disorder of neurotransmitters including L-Glutamate and / or L-Glutamic acid caused by Parkinson's disease, or aminobenzoic acid compounds are used to restore the metabolism of neurotransmitters including L-Glutamate and / or L-Glutamic acid caused by Parkinson's disease to normal.

[0104] In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to regulate the metabolic disorder of glycerophosphate (preferably phosphatidylethanolamine) caused by Parkinson's disease; or aminobenzoic acid compounds are used to restore the metabolic disorder of glycerophosphate (preferably phosphatidylethanolamine) caused by Parkinson's disease to normal.

[0105] The present invention also found that aminobenzoic acid compounds also have therapeutic effects on abnormal brain regions or cognitive impairment in PD patients. In a preferred embodiment of the present invention, aminobenzoic acid compounds can be used to improve motor dysfunction in patients with Parkinson's disease; more preferably, aminobenzoic acid compounds can be used to improve motor dysfunction in patients with chronic Parkinson's disease. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to improve cognitive dysfunction in patients with Parkinson's disease. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to reduce the level of neuroinflammation mediated by microglia derived from the striatum in the brain region of patients with Parkinson's disease. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to alleviate neurotransmitter disorders in the striatum in the brain region of patients with Parkinson's disease. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to reduce the aggregation of α-Syn in the brain region of patients with Parkinson's disease and / or promote the transfer of α-Syn in the brain region of patients with Parkinson's disease. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to reduce the selective mortality of DA neurons in the brain region of patients with Parkinson's disease.

[0106] The present invention also found that aminobenzoic acid compounds also have therapeutic effects on motor dysfunction in patients with PD. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to increase the limb muscle strength of patients with Parkinson's disease. In a preferred embodiment of the present invention, aminobenzoic acid compounds are used to improve the balance ability of patients with Parkinson's disease.

[0107] Uses of Phosphatidylethanolamine

[0108] The present invention also relates to the use of phosphatidylethanolamine for (i) preventing and / or treating intestinal flora disorder caused by Parkinson's disease; and (ii) preparing a drug for preventing and / or treating intestinal flora disorder caused by Parkinson's disease.

[0109] Treatment

[0110] The present invention also relates to a method for preventing and / or treating intestinal flora disorder or metabolic disorder caused by Parkinson's disease, comprising the steps of administering a therapeutically effective amount of an aminobenzoic acid compound to a subject.

[0111] As used in the present invention, the term "prevention" refers to preventing the onset, recurrence or spread of a disease or condition, or one or more symptoms associated with the disease or condition. In one embodiment, such symptoms are known to those skilled in the art to be associated with the disease or condition to be prevented. In a specific embodiment, the term refers to the administration of the compounds provided herein in conjunction with or without other additional active agents before the onset of symptoms for patients with a risk of suffering from a disease or disorder described herein. The term includes the inhibition and reduction of symptoms of a particular disease. In a specific embodiment, patients with a family history of a disease are specifically considered candidates. In addition, patients with a history of recurrent symptoms are also potential candidates for prevention. In this regard, the term "prevention" can be used interchangeably with the term "preventive treatment".

[0112] As used herein, the term "treat" refers to eradicating or ameliorating a disease or condition, or one or more symptoms associated with the disease or condition. In one embodiment, such symptoms are known to those skilled in the art to be associated with the disease or condition to be treated. In a specific embodiment, the term refers to minimizing the spread or worsening of a disease or condition by administering one or more preventive or therapeutic agents to a subject suffering from the disease or condition. In some embodiments, the term refers to administering a compound of the present invention after the onset of symptoms of a particular disease, with or without other additional active agents.

[0113] As used herein, the term "therapeutically effective amount" refers to an amount of a compound sufficient to provide a therapeutic effect in the treatment or management of a disease or disorder, or sufficient to delay or minimize one or more symptoms associated with the disease or disorder. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent that can provide a therapeutic effect in the treatment or management of a disease or disorder when used alone or in combination with other therapies. The term "therapeutically effective amount" can include an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.

[0114] As used in the present invention, the term "subject" is defined herein to include animals, such as mammals, including but not limited to primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In a specific embodiment, the subject is a human.

[0115] To make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are weight percentages and weight parts. The experimental materials and reagents used in the following examples can be obtained from commercial channels unless otherwise specified.

[0116] Unless otherwise specified, the technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the technical field to which the application belongs. It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present application.

[0117] Unless otherwise indicated, the term "or" means and is used interchangeably with the term "and / or".

[0118] As used herein, including the appended claims, singular forms of words such as "a," "an," and "the" include their corresponding plural referents unless the context clearly dictates otherwise.

[0119] Example 1. Preparation of α-Syn preformed fibrils (PFF)

[0120] 500 μg of α-Synuclein was prepared into a 5 mg / mL stock solution using 100 μL sterile PBS, which was placed on a magnetic stirrer and stirred at 1000 rpm at 37° C. for seven days to prepare α-Syn polymers. The α-Syn polymers were further sonicated for 30 seconds (amplitude 10% / 0.5 second pulse interval).

[0121] Example 2. Stereotaxic brain injection

[0122] Anesthesia: The mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital (0.06 mL / 10 g body weight) and fixed on a stereotaxic apparatus. The top of the head was disinfected with iodine, the hair on the head surface was trimmed, and then disinfected again with iodine.

[0123] Stereotaxic brain injection: a midsagittal incision was made, the skin on both sides of the incision was clamped with an artery clamp, and a cotton swab was dipped in 30% H2O2 to wipe the bregma. According to the mouse brain stereotaxic atlas, the position was determined (injection position of bilateral striatum: AP+0.2mm; ML±2.0mm; DV 2.6mm) and a micro-hole dental drill was used to drill holes, and the needle was slowly inserted using a self-made micro-injector with a glass electrode (α-Syn PFF: 5μg (2μL, 0.1μL / min); solvent PBS: (2μL, 0.1μL / min). After the injection was completed, the needle was stopped for 10 minutes and the glass electrode was slowly rotated out.

[0124] Suturing and feeding: After the mouse's head is sutured, it is disinfected again with iodine, and the mouse is placed in a 37°C constant temperature incubator. After it wakes up, it is returned to the cage and fed freely. Three days after the operation, sugar water is given or wet food is added to the cage for continuous feeding.

[0125] Note: 0.3 mL of normal saline was injected subcutaneously before the operation to prevent dehydration during the operation. Erythromycin eye ointment was applied to the eyes to protect the eyes. A thermometer was used to measure the rectal temperature and record the physiological status of the mice before, during and after the operation. A 37°C constant temperature pad was used to keep warm throughout the operation.

[0126] Example 3. Pole climbing experiment

[0127] The pole climbing experiment behavior is used to detect the movement and coordination ability of mice. The device is an iron rod with a diameter of 1 cm and a length of 50 cm placed vertically in an empty mouse cage with a length of 48 cm, a width of 35 cm, and a height of 21 cm. A layer of clean bedding is laid on the bottom, and a gauze ball with a diameter of 2.5 cm is fixed on the top.

[0128] Adaptation period: Place the mouse on the side of the gauze ball with its head facing upwards and its body hanging naturally. The purpose of the training adaptation period is to train the mouse to crawl freely on the climbing pole device. The training is conducted three times, with an interval of 1 hour between each time.

[0129] Experimental period: The placement method of mice was the same as that of the adaptation period. Time was recorded after placement. The recorded indicators included the time when the mouse turned its head downward and the time when the mouse climbed from the top of the climbing pole device to the bottom and left. The non-continuous measurement method was used and the measurement was repeated after an interval of 1 hour. A total of three measurements were taken and the average value was taken.

[0130] Example 4. Muscle strength test

[0131] The mouse muscle strength tester was used to test the muscle strength of the mouse limbs. After turning on the muscle strength tester, the mouse was placed horizontally on the tester, its tail was gently lifted, and the mouse was pulled back at a constant speed. The muscle strength tester would record the maximum muscle strength of the mouse at the moment it left the tester. Intermittent measurement was used to measure continuously for 6 times, with an interval of 1 hour each time, and the average value was used to evaluate the muscle strength of each mouse.

[0132] Example 5. Rotarod assay

[0133] The rotarod test is used to assess the motor coordination and muscle strength of mice. The length of time an animal stays on the rotarod is a measure of the animal's balance, coordination, physical condition, and movement. The longer a mouse stays on the rotarod, the better its motor coordination.

[0134] Adaptation period: Place the mouse in the center of the rotarod apparatus with its head facing inward and its tail at a 45-degree angle. The training adaptation period is in uniform speed mode with a roller speed of 5 r / min, 1 min / time for each mouse, 3 times a day, and training for 3 days.

[0135] Experimental period: After placing the mice on the rotarod for 2 minutes, the uniform acceleration experiment mode was turned on, with a speed of 5-30rpm for 5 minutes. After the experiment began, the mice would run continuously or fall down with the rotarod. After 5 minutes, the rotarod would stop automatically. The system could record the time the mice stayed on the rotarod. The non-continuous measurement method was used, and the measurement was repeated after an interval of 2 hours. The average value was taken for a total of three measurements.

[0136] Example 6. Fecal sample collection and water content determination

[0137] The time for feces collection is fixed at 9:00 to 12:00 every morning. Prepare several empty cages that are consistent with the specifications of the mouse cages, put a thin layer of bedding on the bottom, and gently put the mice in (one per cage). Allow them to move freely for 1 hour without providing food and water. After 1 hour, take out the mice quickly, use clean tweezers, and multiple people pick them out in the fastest time and place them in a 1.5mL EP tube for weighing and recording the wet weight of feces. Then place them in a 50℃ oven overnight, repeat the weighing and record as the dry weight of feces.

[0138] The calculation formula for feces moisture content is: feces moisture content = (feces wet weight - feces dry weight) / feces wet weight.

[0139] Example 7. Fecal 16S rRNA gene sequencing and metagenomic sequencing and extraction

[0140] The mice were anesthetized by intraperitoneal injection of 1.5% sodium pentobarbital (6 mL / kg, intraperitoneal injection) and placed in a supine position on a clean dissecting board. The surface of the mice was disinfected with 75% alcohol. Sterile scissors were used to cut along the ventral abdominal wall of the mice from the genital area to the bottom of the chest cavity, and then the muscle tissue was peeled off to expose the intestine. Clean tweezers were used to squeeze the feces in the colon part of the intestine directly into a 1.5 mL EP tube, which was quickly frozen with liquid nitrogen and stored at -80 degrees for testing.

[0141] At least 1 μg of genomic DNA was extracted from the fecal sample, and the genomic DNA was fragmented using Covaris to shear the DNA sample into fragments of about 400 bp in size. TM The Rapid DNA-Seq kit was used for library preparation. The prepared libraries were sequenced on the Illumina HiSeq X Ten instrument (2×150 bp). The library preparation and sequencing work used the data generated by the Illumina platform for bioinformatics analysis, and the analysis was performed on the Shanghai Major Biotechnology's Bioinformatics Cloud Platform (www.majorbio.com).

[0142] Example 8. Gene prediction and annotation

[0143] Fastp software was used to perform quality control on the original sequencing sequence, remove the adapter sequence in the reads; cut and remove the bases other than A, G, C, and T at the 5' end. The ends of reads with low sequencing quality (sequencing quality value less than Q20) were trimmed; and reads containing N at a ratio of 10% were removed. Small fragments less than 25bp in length after adapter removal and quality trimming were discarded. The assembly software SOAPdenovo-2 was used to splice the optimized sequence to obtain the optimal assembly result. Subsequently, the DADA2 denoising algorithm was used to perform filtering and trimming, error rate modeling, sample inference, merging double-end sequences, constructing ASV tables, annotation classification, and accuracy evaluation, and the ASV (Amplicon Sequence Variant) sequence was obtained by processing the optimized data.

[0144] Example 9. Community diversity analysis

[0145] The Alpha and Beta diversity analyses were performed based on the ASVs obtained using QIIME2 software. The analyses were performed on the Shanghai Major Bioinformatics Cloud Platform (www.majorbio.com).

[0146] Alpha diversity is a comprehensive indicator of richness and evenness in a specific region or ecosystem, which can be evaluated at the ASV level by a series of Alpha diversity indices (such as sobs, chao1, shannon, simpson, coverage, etc.). Then, multiple group comparisons One-way ANOVA analysis was used to detect whether there were significant differences in the Alpha diversity index values ​​between groups.

[0147] Beta diversity refers to the differences in species composition between communities in different habitats along the environmental gradient. The Jaccard distance algorithm in statistics was used to calculate the distance between two samples and construct a distance matrix to show the differences in Beta diversity. PCA, PCoA, NMDS and other analysis methods were used in combination with ANOSIM analysis to evaluate the similarities or differences in the overall community structure between different groups.

[0148] Example 10. Species composition analysis

[0149] The species annotation results of ASV sequences were obtained using the species annotation database (silva138 / 16s_bacteria) and the Bayes annotation method with a classification confidence of 0.7. Based on the species annotation results, the species composition in each group was analyzed using stacked bar charts, Heatmap charts, Venn charts, Circos charts, etc., to obtain information such as the composition and abundance changes of dominant species in each group.

[0150] Example 11. Species Difference Analysis

[0151] One-way ANOVA was used with FDR test correction, Tukey-ramer method and reverse post-hoc test to evaluate the significance level of species abundance differences between groups at the genus level and obtain species with significant differences between groups.

[0152] Example 12. KEGG annotation

[0153] The KEGG Compound database (https: / / www.kegg.jp / kegg / compound / ) was used to classify the metabolites to be identified according to biological processes (Compounds with biological roles) and statistically plotted. The differential metabolites were annotated with metabolic pathways using the KEGG database (https: / / www.kegg.jp / kegg / pathway.htmL) to obtain the pathways in which the differential metabolites participated. The Python package scipy.stats was used for pathway enrichment analysis, and the most relevant biological pathways to the experimental treatment were obtained by Fisher's exact test.

[0154] Example 13. Classification of HMDB compounds

[0155] The HMDB compound classification database (http: / / www.hmdb.ca / ) was used to classify the identified differential metabolites. The classification information of metabolites was obtained by comparing with the HMDB 4.0 database and statistically plotting the names of superclass metabolites and the percentage of metabolites.

[0156] Example 14. PICRUSt2 function prediction

[0157] PICRUSt2 (https: / / github.com / picrust / picrust2) software was used to standardize the species abundance of the obtained ASV sequences according to the built-in reference sequences based on the 16S rRNA copy number contained in each species. The ASV abundance table after correcting the 16S rDNA copy number was obtained. The obtained results were compared with databases such as KEGG to obtain the corresponding functional and abundance information.

[0158] Example 15. BugBase function prediction

[0159] BugBase (https: / / bugbase.cs.umn.edu / index.htmL) software was used to normalize OTUs according to the predicted 16s copy number and then predict microbial phenotypes.

[0160] Example 16. RDA analysis (association and model prediction analysis)

[0161] RDA, or Redundancy Analysis, plots microbial samples and metabolites on the same two-dimensional ordination diagram to present the relationship between sample distribution and metabolites. RDA is mainly used to analyze the association between species or functions and environmental factors.

[0162] Example 17. Correlation Heatmap

[0163] The Spearman correlation coefficient was used to evaluate the correlation between microbial classification and metabolites, and a correlation matrix was constructed. A heat map was used to show the correlation between each microbial classification in the community and each environmental factor variable.

[0164] Example 18. Linear regression and other analysis

[0165] Ranking regression analysis of environmental factors, with metabolites as the x-axis and the Alpha diversity index as the y-axis, a scatter plot was made, and a linear regression analysis was performed and R was marked. 2 , to evaluate the correlation between metabolites and microbial classification.

[0166] Example 19. Development of novel TRPM2 inhibitor aminobenzoic acid compounds has neuroprotective effects in PFF-induced PD mouse model

[0167] This example designs an experimental scheme to test the efficacy of aminobenzoic acid compounds. Compared with the subacute model, this study selected a chronic PD mouse model of PFF brain stereotaxic injection, which can better simulate the pathological changes and behavioral changes of PD. The aminobenzoic acid compounds (3 mg / kg, twice a week, a total of eight times) were injected into the tail vein of the eight-month-old PD mouse model to explore the effect of aminobenzoic acid compounds on the PFF-induced PD mouse model. The time flow chart of the overall experiment is shown in the figure below. Figure 1A shown.

[0168] Behavioral tests and pathological analysis were performed on mice at 9 months old. First, administration of aminobenzoic acid compounds and PFF modeling did not affect the weight of mice, indicating that the drugs had no significant effect on the development of mice ( Figure 1B The classic rotarod, pole climbing and muscle strength test were further used to detect the movement and balance ability of mice. The results showed that aminobenzoic acid compounds significantly increased the time that PD mice stayed on the rotarod, reduced the head turning time and total time in pole climbing behavior, and significantly improved the reduction in limb muscle strength of mice caused by PFF ( Figure 1C -E), the above data show that the motor balance ability of PD model mice is impaired, and aminobenzoic acid compounds significantly reduce the behavioral defects of PD mice. Therefore, this study simultaneously used the Y maze test to detect the cognitive ability of mice. The autonomous alternation rate of mice in the WT-PFF group was significantly lower than that in the control group, indicating that the cognitive ability of PD mice was impaired. The autonomous alternation rate of WT-PFF-aminobenzoic acid compound mice was significantly higher than that of the WT-PFF group ( Figure 1F ), indicating that the cognitive function of mice in the WT-PFF-aminobenzoic acid compound group was better. The above behavioral test results showed that aminobenzoic acid compounds significantly improved the motor dysfunction and learning and memory impairment of PD mice.

[0169] The results of brain pathological immunofluorescence staining showed that the number of DA neurons in the substantia nigra of the WT-PFF group was significantly lower than that in the control group, and the number of microglia and astrocytes per unit area was significantly increased, indicating that the level of neuroinflammation in this brain region was significantly increased. Aminobenzoic acid compounds can significantly reduce the loss of DA neurons in the substantia nigra and the number of microglia per unit area of ​​the striatum, but do not affect the number of astrocytes per unit area of ​​the striatum, suggesting that aminobenzoic acid compounds participate in the selective loss of DA neurons by reducing the level of microglia-mediated neuroinflammation ( Figure 2A -E).

[0170] By detecting neurotransmitters in the striatum through HPLC-MS, this study found that the levels of DA and its metabolite homovanillic acid (HVA) in the WT-PFF group were significantly reduced, and the levels of DA and HVA in the WT-PFF-aminobenzoic acid compound group were increased compared with the WT-PFF group, but not significantly ( Figure 2F DA is the precursor of adrenaline / norepinephrine. DA can be converted to norepinephrine under the action of dopamine β-hydroxylase, and norepinephrine is methylated to adrenaline under the action of phenylethylamine-N-methyltransferase. Studies have shown that β2adrenergic receptor (β2AR) ligands regulate the transcription of SNCA through acetylation of histone 3 lysine 27 of SNCA promoter and enhancer. In an 11-year follow-up of 4 million Norwegians, β2AR agonist salbutamol (a brain-penetrating asthma drug) was associated with a reduced risk of PD. β2AR activators have neuroprotective effects in both PD model mice and cell models, indicating that stimulating adrenaline receptors reduces the risk of PD and clarifies that adrenaline is involved in the disease process of PD. In this study, it was found that aminobenzoic acid compounds did not effectively regulate the relative content of norepinephrine, but could significantly increase the content of adrenaline in the striatum of PD mouse models and improve the behavioral phenotype of PD mice. The above data indicate that aminobenzoic acid compounds can not only effectively alleviate the motor dysfunction of PD mice, but also further alleviate the disease phenotype of PD by affecting striatal microglial neuroinflammation and regulating the content of adrenaline.

[0171] Example 20: Aminobenzoic acid compounds reduce the migration and aggregation of PFFs in the brain of PD mice

[0172] This study evaluated the diffusion rate of aminobenzoic acid compounds to various brain regions in PD mice. Figure 3A As shown in Figure 2, the pSer129-α-Syn brain region aggregation in the SNc of the WT-PFF-aminobenzoic acid compound group was reduced compared with the WT-PFF group. Further, according to the second edition of the mouse brain stereotaxic atlas, we divided the mouse brain from Bregma1.78mm-3.52mm from front to back into nine regions to evaluate the aggregation of pSer129-α-Syn. The statistical diffusion rate heat map is shown in Figure 2. Figure 3B As shown, aminobenzoic acid compounds reduced the aggregation of pSer129-α-Syn in the whole brain area and reduced the transfer rate of pSer129-α-Syn. Figure 3CThe representative schematic diagram of pSer129-α-Syn immunofluorescence staining in the primary motor cortex, cortex, striatum, hippocampal CA1, and hippocampal dentategyrus brain regions is shown. The above data indicate that aminobenzoic acid compounds can also participate in the pathological phenotype and behavioral disorders of PD by affecting the aggregation and transfer of α-Syn.

[0173] Example 21 Inhibition of TRPM2 function improves constipation phenotype and intestinal flora disturbance in PD mice

[0174] In addition to typical motor behavior disorders, PD also has non-motor dysfunction. Among them, the most important manifestation of autonomic dysfunction in PD patients is constipation, with an incidence rate as high as 73%. At the same time, constipation can occur up to 20 years before motor symptoms. Constipation not only brings troubles to patients' lives, but also increases the risk of PD by at least twice. Therefore, while exploring the central protective effect of aminobenzoic acid compounds on PD mice, we combined pharmacological intervention of aminobenzoic acid compounds and TRPM2, and tested the constipation of PD mice at different times to explore the effect of aminobenzoic acid compounds on peripheral symptoms of PD.

[0175] First, this study tested the weight and water content of feces of PD mice at the 3rd, 6th, and 9th months, as shown in Figure 4A. The results showed that the total weight and water content of feces of PD mice were significantly reduced to varying degrees compared with the WT control group, and the administration of PFF to TRPM2-KO mice did not significantly affect the total weight and water content of feces ( Figure 4B -C). We further injected aminobenzoic acid compounds into the tail vein of the PD mouse model at the 8th month, with an injection dose of 3 mg / kg, twice a week, for 1 month. The experimental results showed that aminobenzoic acid compounds can significantly reduce the decrease in fecal water content in the PD mouse model and restore it to normal levels ( Figure 4D ). To further explore the specific mechanism by which TRPM2 affects constipation phenotype, we collected the feces of mice aseptically, quickly froze them in liquid nitrogen, and sent them to Meiji for 16S rDNA sequencing and species identification of bacteria. The study found that the microbial diversity (Sobs, Ace, Chao) of PD model mice was significantly higher than that of the control group. Both aminobenzoic acid compounds and TRPM2-KO can significantly restore the microbial diversity to normal levels by intervening in TRPM2 ( Figure 4F -G). The above data indicate that intervening TRPM2 can regulate the diversity of intestinal flora and mediate the early constipation symptoms of PFF-induced PD mice.

[0176] Example 22 Inhibition of TRPM2 function reduces species richness of intestinal flora in PD mice

[0177] Furthermore, this study used the Rank abundace curve to reflect the number of high-abundance and rare amplicon sequence variants (ASVs) in the communities among the groups. Figure 5A -B), Pananalysis and Core analysis were used to evaluate the total species richness and number of core species in the environment among the groups. The data showed that the sequencing sample size was sufficient, and the species richness of the WT-PFF group was the highest among all groups ( Figure 5C -F).

[0178] A hierarchical clustering tree at the genus level was applied ( Fig. 6A , 7A) and non-metric multidimensional scaling (NMDS) were used to classify the intestinal microbiota of the mice in the aminobenzoic acid group at the genus level and the ASV level ( Figure 6C , 7C), pharmacological and genetic intervention of TRPM2 both resulted in genus-level components in the PD disease state that were similar to those of the WT-Vehicle group, suggesting that TRPM2 can be used as a major target for intervention in changes in the PD intestinal flora to treat constipation. Comparison of PD mice and WT controls showed that at the genus level, Dubosiella, Faecalibaculum, Coriobacteriaceae-UCG-002 and other flora were significantly reduced, while Candidatus-Saccharimonas, Lactococcus, norank-f-Ruminococcaceae, Lachnospiraceae-NK4A136-group, Bacillus and other flora were significantly increased. Further typing analysis at the genus level showed that the main bacterial species that affected the intestinal flora at the genus level in each group of aminobenzoic acid compound intervention were Lactobacillus and Dubosiella ( Figure 6B ). The main bacterial species affecting the intestinal flora in each group at the genus level of TRPM2-KO intervention were Lactobacillus, Dubosiella, Muribaculaceae, Turicibacter, and Lactococcus ( Figure 7B). In summary, both pharmacological and genetic inhibition of TRPM2 function will have a major impact on Lactobacillus and Dubosiella. Therefore, we will focus on Lactobacillus and Dubosiella.

[0179] Through the One-Way Anova analysis of a single bacterial community, aminobenzoic acid compounds and TRPM2-KO can significantly and effectively reduce the decrease in Dubosiella content in PD mice, and there are also synergistic changes in bacterial communities such as Coriobacteriaceae-UCG-002 ( Fig.6D , 7D). In summary, the above data show that both pharmacological and genetic interventions in TRPM2 can regulate and improve the composition of the intestinal flora of PD mice, mainly regulating Lactobacillus and Dubosiella. On the other hand, this study analyzed and clarified that Dubosiella's functional regulation in response to TRPM2 is involved in the disease pathogenesis of PD, further affecting the diversity and disorder of the intestinal flora. Based on the results of this study, Dubosiella has the potential to develop into a probiotic. However, in addition to exploring the mechanism of action of key flora, because the system of intestinal flora is extremely complex and diverse, we further classified the phenotypes of all flora to further evaluate the impact of TRPM2 on the intestinal flora.

[0180] Example 22 Inhibition of TRPM2 function reduces colonic OS-related microbial abundance

[0181] By analyzing the phenotype of the microbiota, it was found that aminobenzoic acid compounds inhibited TRPM2 function and TRPM2 gene knockout mainly affected the OS-tolerant intestinal microbiota ( Fig. 8A ), specific flora types such as Figure 8B As shown in the figure, it shows that systemic intervention of TRPM2 can alleviate the disorder of OS-related intestinal flora at the PD disease level. OS-related enzymes were analyzed at the metabolic level, such as Figure 8C As shown in the results, PFF leads to increased levels of enzymes such as NADPH, Superoxide dismutase, Glutathione peroxidase, and NADH peroxidase in feces, which can be reduced to normal levels by intervening in TRPM2. This suggests that as a receptor of OS, intervening in TRPM2 can intervene in the disorder of intestinal flora by affecting the flora related to conventional OS sensitivity, thereby alleviating the intestinal disorder of PD.

[0182] PICRUSt2 was further used for functional prediction analysis to obtain KEGG pathways 1-3 ( Fig. 9A ab) corresponding to the functional changes, the PFF group pathway metabolic pathway level increased, the metabolic pathway related to human diseases, cellular processes, environmental information processing level decreased, aminobenzoic acid compounds and TRPM2-KO can be restored to normal levels by intervening TRPM2. Further refinement, TRPM2 may participate in the regulation of intestinal disorders by regulating cell membrane transport, damage and repair, energy metabolism, amino acid metabolism, ABC transporters, carbon metabolism and other processes in the intestinal flora.

[0183] So how does intervening TRPM2 affect the flora and further affect the pathological changes in the brain of mice? The gut-brain axis refers to the two-way exchange of signals between the gut flora and the brain mediated by neuroendocrine pathways, neurons, and immune cells. On the one hand, the gut flora can produce inflammatory factors that pass through the blood-brain barrier, leading to neuroinflammation and intervening in the progression of PD; on the other hand, the gut flora can produce neuroactive substances, such as norepinephrine, serotonin, DA, serine, and short-chain fatty acids. The signals produced by the metabolites can be sensed by the afferent fibers of the vagus nerve and transported to the brain. We further tested the metabolites of feces and the indicators related to colon inflammation in mice.

[0184] Example 23 Intervention of TRPM2 reshapes the metabolic pathways and neurotransmitter disorders in the gastrointestinal tract of PD mice

[0185] In order to clarify the changes in fecal metabolic levels of PD mice after intervention of TRPM2, this study conducted non-targeted metabolomics determination on the feces of each group of mice. The QC sample evaluation of metabolites measured in positive and negative ion modes is shown in the figure below. Fig. 10A -B, the horizontal axis of the RSD distribution plot is the standard deviation / mean, that is, RSD (%), and the vertical axis represents the cumulative proportion of the ion peak. The overall data qualification evaluation standard is RSD <0.3, and the cumulative proportion of the peak is >70%. The dotted line in the figure represents before pretreatment, and the solid line represents after pretreatment. The pretreatment method is to remove missing values ​​greater than 20% in each group and use the minimum value to fill the missing values. In order to further display intuitively, PCA and partial least squares discriminant analysis (Partial Least-Squares Discriminant Analysis, PLS-DA) were used to cluster the positive and negative ion metabolites of the aminobenzoic acid compound group and the TRPM2-KO group. There were large differences between the WT-PFF and WT-Vehicle and WT-PFF-aminobenzoic acid compound groups, and the composition of the WT-Vehicle and WT-PFF-aminobenzoic acid compound groups was relatively close ( Fig. 10C-D). The results of the TRPM2-KO group were similar. The WT-PFF and WT-Vehicle, TRPM2-KO-Vehicle, and TRPM2-KO-PFF groups showed significant differences. The compositions of the WT-Vehicle, TRPM2-KO-Vehicle, and TRPM2-KO-PFF groups were relatively close ( Fig.10E -F), suggesting that intervention of TRPM2 reshaped the metabolic pathways of the gastrointestinal tract of PD mice. The Venn diagram of metabolites between the groups is shown in Figure 10G As shown, the metabolite KEGG compounds were further classified, among which amino acids, phospholipids, fatty acids, monosaccharides, and neurotransmitters were the most numerous. Neurotransmitters are molecules that amplify, transmit, and convert signals within cells. Neurotransmitters are also basic regulators of neuron growth, differentiation, and survival, and they play an important role in information transmission throughout the nervous system. Therefore, we further conducted a systematic analysis of the metabolites related to neurotransmitters.

[0186] In PD, the extensive damage of DA neurons leads to a significant decrease in the secretion of neurotransmitter DA in the brain. Other neurotransmitters including glutamate, GABA, Serotonin, histamine, acetylcholine and adrenaline also have relevant changes in PD. The intestinal microbiota can release relevant neuroactive metabolites such as neurotransmitters or their precursors, which can quickly transmit signals to the brain through blood circulation, local stimulation of the enteric nervous system and rapid signal transduction of the vagus nerve, affecting the concentration of related neurotransmitters and their precursors, further affecting central function. This shows that the neurotransmitter synthesis pathway in the intestine can directly or indirectly affect the neuronal activity of the brain. Therefore, we analyzed the clustering heat maps of neurotransmitters between the aminobenzoic acid compound groups, as shown below. Fig.11 As shown in A, there is an obvious clustering phenomenon among different groups. We further performed statistical analysis on single neurotransmitters.

[0187] Cluster heatmaps and VIP histograms were further used to show the changes in neurotransmitters between WT-Vehicle / WT-PFF, WT-PFF-aminobenzoic acid compounds / WT-PFF, and TRPM2-KO-PFF / WT-PFF. Fig.12As shown, the results showed that the levels of Serotonin, 5-Hydroxy-L-tryptophan, L-Glutamate, L-Glutamic acid, L-Tyrosine, etc. were significantly increased in the PD mouse model. Both aminobenzoic acid compounds and TRPM2-KO can reduce the above-related neurotransmitters to normal levels to varying degrees. Among them, Serotonin is a key regulator of gastrointestinal motility and secretion, and about 90% of Serotonin in the human body is secreted by enterochromaffin cells of the intestinal epithelium. The Serotonin receptors expressed in gastrointestinal tissues are diverse and widely distributed, and are involved in the regulation of gastrointestinal function.

[0188] At the same time, the contents of phosphatidylethanolamine PE (15:0 / 20:2 (11Z, 14Z)), PE (15:0 / 20:4 (8Z, 11Z, 14Z, 17Z)), 1-palmitoyl-2-stearoyl-sn-glycerol DG (16:0 / 18:4 (6Z, 9Z, 12Z, 15Z) / 0:0) were significantly reduced in the PD mouse model, among which PE (15:0 / 20:4 (8Z, 11Z, 14Z, 17Z)) is a glycerophospholipid (hereinafter referred to as PE). Studies have shown that the PE content in the SNc of sporadic PD patients is significantly lower than that of the control group, and levodopa treatment can correct it back to normal levels, indicating that PE plays a very important role in the pathogenesis of PD. This study first found that in the PFF-induced PD chronic mouse model, the PE level in the intestine was significantly reduced, and intervention in TRPM2 could significantly correct PE back to normal levels. Combined with existing research results, it shows that TRPM2 plays a role in alleviating the progression of PD by affecting the content of PE.

[0189] TRPM2, as a sensor of OS, can also regulate physiological processes such as cell autophagy and endoplasmic reticulum stress. Our study found for the first time that in the colon tissue of PD mouse model, the constipation phenotype of mice was associated with increased available serotonin in the circulation and decreased PE content. This study clarified the mechanism by which TRPM2 can treat PD and relieve constipation in the course of PD disease by regulating the levels of PE and serotonin in the intestine. At the same time, intervention of TRPM2 can also regulate the disorder of neurotransmitters such as L-Glutamate and L-Glutamic acid in the intestine of PD mice and adjust them to normal levels. It is clear that inhibiting TRPM2 function by aminobenzoic acid compounds and TRPM2 gene knockout can reshape the neurotransmitter disorder secreted by the intestinal flora of PD mice induced by PFF.

[0190] Those skilled in the art will appreciate that the above-mentioned embodiments are specific examples for implementing the present invention, and in actual applications, various changes may be made thereto in form and detail without departing from the spirit and scope of the present invention.

Claims

1. Uses of aminobenzoic acid compounds: (i) prevention and / or treatment of Parkinson's disease and its complications; and (ii) preparing a medicament for preventing and / or treating Parkinson's disease or its complications; in, The structures of aminobenzoic acid compounds are as follows:

2. The use according to claim 1, characterized in that The complication of Parkinson's disease is non-motor dysfunction caused by Parkinson's disease, and the non-motor dysfunction caused by Parkinson's disease includes constipation caused by Parkinson's disease, intestinal flora disorder caused by Parkinson's disease and / or metabolic disorder caused by Parkinson's disease.

3. The use according to claim 2, characterized in that: The intestinal flora is an OS-tolerant intestinal flora (preferably Dubosiella and / or Lactococcus).

4. The use according to claim 2, characterized in that: The aminobenzoic acid compound regulates the intestinal flora disorder of Parkinson's disease patients by increasing the amount of Dubosiella in the intestinal tract of Parkinson's disease patients or reducing the amount of Dubosiella in the intestinal tract of Parkinson's disease patients.

5. The use according to claim 2, characterized in that: The aminobenzoic acid compound regulates the intestinal flora disorder of Parkinson's disease patients by reducing the amount of Lactococcus in the intestinal tract of Parkinson's disease patients or increasing the amount of Lactococcus in the intestinal tract of Parkinson's disease patients.

6. The use according to claim 2, characterized in that: The metabolic disorder caused by Parkinson's disease includes: sugar metabolism disorder caused by Parkinson's disease, fat metabolism disorder caused by Parkinson's disease and / or neurotransmitter metabolism disorder caused by Parkinson's disease.

7. The use according to claim 6, characterized in that The fat metabolism disorder caused by Parkinson's disease includes glycerophosphate metabolism disorder (preferably phosphatidylethanolamine metabolism disorder).

8. The use according to claim 6, characterized in that The neurotransmitter disorder caused by Parkinson's disease includes L-Glutamate and / or L-Glutamic acid metabolism disorder.

9. Uses of phosphatidylethanolamine: (i) Preventing and / or treating intestinal flora disturbance caused by Parkinson's disease; (ii) preparing a drug for preventing and / or treating intestinal flora disturbance caused by Parkinson's disease.

10. A method for preventing and / or treating intestinal flora disorder and / or metabolic disorder caused by Parkinson's disease, comprising the steps of: A therapeutically effective amount of an aminobenzoic acid compound is administered to the subject.